MarketCap
Facebook
X
TelegramQuarterly report 2022-Q2
added 08-08-2022
Turning Point Therapeutics Operating Income 2011-2026 | TPTX
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Turning Point Therapeutics
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -238 M | -162 M | -77.7 M | -25.6 M | -16.7 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -16.7 M | -238 M | -104 M |
Quarterly Operating Income Turning Point Therapeutics
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -124 M | -74.9 M | - | -66.7 M | -56.7 M | -36 M | -47.9 M | -18.5 M | -32.7 M | -62.6 M | -23.1 M | -22.1 M | -18.5 M | -14.1 M | -9.48 M | -6.13 M | -5.17 M | -4.86 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -4.86 M | -124 M | -36.7 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Burford Capital Limited
BUR
|
242 M | $ 4.74 | 0.53 % | $ 761 M |  Britain |
 |
Cabaletta Bio
CABA
|
-172 M | $ 3.33 | 2.15 % | $ 335 M |  USA |
 |
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M |  Germany |
 |
Can-Fite BioPharma Ltd.
CANF
|
-9.95 M | $ 3.07 | 0.49 % | $ 5.05 M |  Israel |
 |
Acorda Therapeutics
ACOR
|
-265 M | - | -24.86 % | $ 820 K | USA |
 |
Adverum Biotechnologies
ADVM
|
-139 M | - | - | $ 86.2 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
502 M | $ 332.58 | -2.01 % | $ 43.6 B | USA |
 |
AlloVir
ALVR
|
-46.2 M | - | 4.14 % | $ 49.1 M | USA |
 |
Genfit SA
GNFT
|
31.8 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M | France |
 |
Aligos Therapeutics
ALGS
|
-88 M | $ 7.51 | -14.07 % | $ 74.2 M | USA |
 |
Allakos
ALLK
|
-196 M | - | - | $ 28.6 M | USA |
 |
Esperion Therapeutics
ESPR
|
60.3 M | $ 2.11 | 2.77 % | $ 439 M | USA |
 |
Evogene Ltd.
EVGN
|
-31 M | $ 0.82 | - | $ 27.9 M | Israel |
 |
Applied Molecular Transport
AMTI
|
-127 M | - | - | $ 10.1 M | USA |
|
Forte Biosciences
FBRX
|
-70.7 M | $ 32.35 | -0.2 % | $ 419 M | USA |
 |
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Applied Therapeutics
APLT
|
-64.5 M | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
-62.6 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
-70.8 M | - | -13.39 % | $ 1.45 M | USA |
 |
Galapagos NV
GLPG
|
-166 M | $ 28.99 | 0.36 % | $ 2.69 B |  Belgium |
 |
Amphastar Pharmaceuticals
AMPH
|
140 M | $ 21.36 | -0.09 % | $ 998 M | USA |
 |
Genmab A/S
GMAB
|
2.64 B | $ 29.02 | -0.14 % | $ 18.6 B |  Danmark |
 |
GT Biopharma
GTBP
|
-12.4 M | $ 0.38 | -3.34 % | $ 2.1 M | USA |
 |
BioNTech SE
BNTX
|
15.3 B | $ 99.43 | 1.03 % | $ 27.2 B | Germany |
 |
Advaxis
ADXS
|
-36.3 M | - | -9.65 % | $ 45.9 M | USA |
 |
Hoth Therapeutics
HOTH
|
-12.4 M | $ 0.68 | 4.58 % | $ 9.39 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.67 M | - | 5.93 % | $ 314 M |  Canada |
 |
Harmony Biosciences Holdings
HRMY
|
208 M | $ 29.37 | 0.27 % | $ 1.69 B | USA |
 |
AgeX Therapeutics
AGE
|
-24 M | - | -10.17 % | $ 12.2 K | USA |
 |
ImmuCell Corporation
ICCC
|
1.65 M | $ 7.61 | -1.55 % | $ 68.7 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-210 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
23.5 M | $ 1.54 | -1.28 % | $ 396 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-17.7 M | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
-71.1 M | $ 4.18 | 0.6 % | $ 447 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-12.2 M | $ 24.39 | -2.79 % | $ 3.1 B | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
-9.95 M | - | -2.5 % | $ 5.88 M | USA |
|
Immatics N.V.
IMTX
|
-86.3 M | $ 10.9 | -0.46 % | $ 686 M | Germany |
 |
AIkido Pharma
AIKI
|
-55.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Incyte Corporation
INCY
|
1.51 B | $ 97.43 | -0.27 % | $ 19 B | USA |
 |
BioDelivery Sciences International
BDSI
|
37.1 M | - | -4.8 % | $ 255 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-271 M | $ 1.46 | -1.49 % | $ 389 M | Britain |
 |
BeiGene, Ltd.
BGNE
|
447 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Innate Pharma S.A.
IPHA
|
-47.8 M | $ 1.71 | 4.91 % | $ 235 M | France |